The Longevity Signal Guide
The longevity space is loud. Here’s how to tell what’s backed by real human data from what’s riding a podcast moment. Education, not medical advice.
1. Human data beats mouse data, every time
Most longevity headlines come from animal or cell studies. They’re interesting, not conclusive. Before you act on anything, ask: was this shown in humans, at a real dose, over a real timeframe?
- “Extends lifespan in mice” is a starting point, not a recommendation.
- Look for randomized human trials, not just observational links.
- A mechanism that sounds good is not the same as an outcome that happened.
2. Follow the incentive
When the person explaining a compound also sells it, treat the claim as marketing until proven otherwise. The most-hyped longevity protocols almost always have a storefront attached.
3. The compounds actually being studied
Rapamycin, NAD+ precursors, senolytics, and certain peptides have real research programs, with real open questions. Knowing where the evidence is strong versus thin is the whole game.
- Strong interest, early human data: rapamycin, some senolytics.
- Popular but contested: many NAD+ precursor claims.
- Mostly preclinical: a lot of the “stack.”
We weigh this every week.
Rapaline separates the longevity signal from the supplement-bro noise, with the evidence attached. Free.
Subscribe free →Rapaline is independent education and news, not medical advice. Nothing here is a recommendation to buy, use, or dose any compound. Talk to a qualified clinician about your health.